Stephen L. Bacharach
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephen L. Bacharach has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
David M. Thomasson
Imaging Sciences Program, The National Institutes of Health, Bldg 10, Rm 1C401, NIH, Bethesda, MD 20892, USA
1 shared publicationDavid Sellers
National Institutes of Health, Bethesda, MD, USA
1 shared publicationJames C. Yang
National Institutes of Health, Bethesda, MD, USA
1 shared publicationJoann M. Carson
National Institutes of Health, Bethesda, MD, USA
1 shared publication- Jorge A. Carrasquillo
Memorial Sloan Kettering Cancer Center
1 shared publication - Karen A. Kurdziel
Molecular Imaging Program, National Cancer Institute, Bethesda, USA
1 shared publication
Latest Publications
- Open Access
- 1 May 2007
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 48 (5) , 677-679
PET/CT Attenuation Correction: Breathing Lessons
- 1 May 2007
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 48 (5) , 677-679
Open AccessPET/CT Attenuation Correction: Breathing Lessons
- 1 December 2005
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 2 (4) , 329-334
Imaging approaches for monitoring chemotherapy
- 1 December 2005
- Published by Elsevier in Drug Discovery Today: Technologies
- Vol. 2 (4) , 329-334
Imaging approaches for monitoring chemotherapy
- 1 July 2004
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 11 (4) , 388-392
The new-generation positron emission tomography/computed tomography scanners: Implications for cardiac imaging
- 1 July 2004
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 11 (4) , 388-392
The new-generation positron emission tomography/computed tomography scanners: Implications for cardiac imaging
- 1 January 2003
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (1) , 46-53
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans
The standardized uptake value (SUV) and the slope of the Patlak plot (K) have both been proposed as indices to monitor the progress of disease during cancer therapy. Although a good correlation has been reported between SUV and K, they are not equivalent, and may not be equally affected by metabolic changes occurring during disease progression or therapy. We wished to compare changes in tumor SUV with changes in K during serial positron emission tomography (PET) scans for monitoring therapy. Thirteen patients enrolled in a protocol to treat renal cell carcinoma metastases were studied. Serial dynamic fluorodeoxyglucose (FDG) PET scans and computed tomography (CT) and magnetic resonance (MR) scans were performed once prior to treatment, once at 36±2 days after the start of treatment, and (in 7/13 subjects, 16/27 lesions) a third time at 92±9 days after the start of treatment. This resulted in a total of 33 scans, and 70 tumor Patlak and SUV values (one value for each lesion at each time point). SUV and K were measured over one to four predefined tumors/patient at each time point. The input function was obtained from regions of interest over the heart, combined, if necessary, with late blood samples. Over all tumors and scans, SUV and K correlated well (r=0.97, PK (r=0.73, Pr=0.47, P=NS), and so could not be used to determine the "correct" PET index. Absolute values of SUV and K correlated well over the patient population. However, when monitoring individual patient therapy serially, large differences in the % changes in the two indices were occasionally found, sometimes sufficient to produce opposing conclusions regarding the progression of disease.
- 1 January 2003
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 30 (1) , 46-53
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans
The standardized uptake value (SUV) and the slope of the Patlak plot (K) have both been proposed as indices to monitor the progress of disease during cancer therapy. Although a good correlation has been reported between SUV and K, they are not equivalent, and may not be equally affected by metabolic changes occurring during disease progression or therapy. We wished to compare changes in tumor SUV with changes in K during serial positron emission tomography (PET) scans for monitoring therapy. Thirteen patients enrolled in a protocol to treat renal cell carcinoma metastases were studied. Serial dynamic fluorodeoxyglucose (FDG) PET scans and computed tomography (CT) and magnetic resonance (MR) scans were performed once prior to treatment, once at 36±2 days after the start of treatment, and (in 7/13 subjects, 16/27 lesions) a third time at 92±9 days after the start of treatment. This resulted in a total of 33 scans, and 70 tumor Patlak and SUV values (one value for each lesion at each time point). SUV and K were measured over one to four predefined tumors/patient at each time point. The input function was obtained from regions of interest over the heart, combined, if necessary, with late blood samples. Over all tumors and scans, SUV and K correlated well (r=0.97, PK (r=0.73, Pr=0.47, P=NS), and so could not be used to determine the "correct" PET index. Absolute values of SUV and K correlated well over the patient population. However, when monitoring individual patient therapy serially, large differences in the % changes in the two indices were occasionally found, sometimes sufficient to produce opposing conclusions regarding the progression of disease.